179 related articles for article (PubMed ID: 24595274)
1. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
Cheng NC; van Zandwijk N; Reid G
PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
[TBL] [Abstract][Full Text] [Related]
2. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
3. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
[TBL] [Abstract][Full Text] [Related]
4. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
[TBL] [Abstract][Full Text] [Related]
5. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
[TBL] [Abstract][Full Text] [Related]
6. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
Alghisi GC; Ponsonnet L; Rüegg C
PLoS One; 2009; 4(2):e4449. PubMed ID: 19212436
[TBL] [Abstract][Full Text] [Related]
7. A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.
Hoffmann S; He S; Jin M; Ehren M; Wiedemann P; Ryan SJ; Hinton DR
BMC Ophthalmol; 2005 Jun; 5():16. PubMed ID: 15987521
[TBL] [Abstract][Full Text] [Related]
8. Vitronectin-activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells.
Shen J; Zhu Y; Zhang S; Lyu S; Lyu C; Feng Z; Hoyle DL; Wang ZZ; Cheng T
Cell Prolif; 2021 Apr; 54(4):e13012. PubMed ID: 33656760
[TBL] [Abstract][Full Text] [Related]
9. Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis.
Bagnato GL; Irrera N; Pizzino G; Santoro D; Roberts WN; Bagnato G; Pallio G; Vaccaro M; Squadrito F; Saitta A; Altavilla D; Bitto A
Clin Sci (Lond); 2018 Jan; 132(2):231-242. PubMed ID: 29237724
[TBL] [Abstract][Full Text] [Related]
10. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.
Ruffini F; Graziani G; Levati L; Tentori L; D'Atri S; Lacal PM
Int J Cancer; 2015 Mar; 136(6):E545-58. PubMed ID: 25284767
[TBL] [Abstract][Full Text] [Related]
12. Small molecule integrin antagonists in cancer therapy.
Paolillo M; Russo MA; Serra M; Colombo L; Schinelli S
Mini Rev Med Chem; 2009 Oct; 9(12):1439-46. PubMed ID: 19929817
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of cilengitide on inflammation in chondrocytes under excessive mechanical stress.
Hirose N; Okamoto Y; Yanoshita M; Asakawa Y; Sumi C; Takano M; Nishiyama S; Su SC; Mitsuyoshi T; Kunimatsu R; Tanne K; Tanimoto K
Cell Biol Int; 2020 Apr; 44(4):966-974. PubMed ID: 31876323
[TBL] [Abstract][Full Text] [Related]
14. CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Komiya E; Ohnuma K; Yamazaki H; Hatano R; Iwata S; Okamoto T; Dang NH; Yamada T; Morimoto C
Biochem Biophys Res Commun; 2014 May; 447(4):609-15. PubMed ID: 24747072
[TBL] [Abstract][Full Text] [Related]
15. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
Pan X; Yi M; Liu C; Jin Y; Liu B; Hu G; Yuan X
Bioengineered; 2022 Feb; 13(2):4557-4572. PubMed ID: 35142593
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
Becker A; von Richter O; Kovar A; Scheible H; van Lier JJ; Johne A
J Clin Pharmacol; 2015 Jul; 55(7):815-24. PubMed ID: 25683324
[TBL] [Abstract][Full Text] [Related]
17. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
[TBL] [Abstract][Full Text] [Related]
18. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
20. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.
Bretschi M; Cheng C; Witt H; Dimitrakopoulou-Strauss A; Strauss LG; Semmler W; Bäuerle T
J Cancer Res Clin Oncol; 2013 Apr; 139(4):573-83. PubMed ID: 23229276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
